Get the Stockscreener App
45.93
8.50%
3.60
After Hours:
45.82
-0.11
-0.24%
Avidity Biosciences Inc stock is traded at $45.93, with a volume of 1.16M.
It is up +8.50% in the last 24 hours and up +4.39% over the past month.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
See More
Previous Close:
$42.33
Open:
$42.12
24h Volume:
1.16M
Relative Volume:
0.77
Market Cap:
$5.30B
Revenue:
$10.60M
Net Income/Loss:
$-252.45M
P/E Ratio:
-14.82
EPS:
-3.1
Net Cash Flow:
$-158.91M
1W Performance:
+5.59%
1M Performance:
+4.39%
6M Performance:
+79.98%
1Y Performance:
+619.91%
1-Day Range:
$42.00
$46.35
1-Week Range:
$41.01
$46.94
52-Week Range:
$4.825
$48.80
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences' SWOT analysis: RNA stock poised for growth in muscle disease therapies - Investing.com UK
Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024? - Insider Monkey
Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024? - Yahoo Finance
D. E. Shaw & Co. Inc. Has $30.19 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Fred Alger Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024? - Insider Monkey
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024? - Yahoo Finance
Darwin Global Management Ltd. Purchases New Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
7 Best Performing Long Term Stocks in 2024 - Insider Monkey
Avidity Biosciences to Participate in Upcoming Investor Conference - StockTitan
Avidity Biosciences CFO sells over $500k in company stock By Investing.com - Investing.com South Africa
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by American Century Companies Inc. - MarketBeat
Goldman Sachs sees multi-blockbuster potential for Avidity Biosciences stock By Investing.com - Investing.com Canada
The Goldman Sachs Group Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - MarketBeat
Farallon Capital Management LLC Has $204,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Analysts - MarketBeat
Avidity Biosciences executive sells over $1 million in company stock By Investing.com - Investing.com South Africa
Avidity Biosciences executive sells over $578k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences executive sells over $1 million in company stock By Investing.com - Investing.com Canada
Avidity Biosciences CFO sells over $500k in company stock By Investing.com - Investing.com Canada
Avidity Biosciences executive sells over $578k in stock - Investing.com
Avidity Biosciences executive sells over $578k in stock - Investing.com India
Avidity Biosciences CEO sells over $1.4 million in company stock - Investing.com India
Avidity Biosciences CEO sells over $1.4 million in company stock - Investing.com
Avidity Biosciences executive sells over $1 million in company stock By Investing.com - Investing.com UK
Avidity Biosciences CFO sells over $500k in company stock - Investing.com India
Avidity Biosciences CFO sells over $500k in company stock - Investing.com
Avidity Biosciences CEO sells over $1.4 million in company stock By Investing.com - Investing.com UK
Avidity Biosciences CFO sells over $500k in company stock By Investing.com - Investing.com UK
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
Avoro Capital Advisors LLC Buys 680,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
377,400 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Acquired by Renaissance Technologies LLC - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 5,000 Shares - MarketBeat
Victory Capital Management Inc. Increases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences director sells shares worth over $228k By Investing.com - Investing.com South Africa
Avidity Biosciences director sells shares worth over $228k By Investing.com - Investing.com Canada
Avidity Biosciences director sells shares worth over $228k - Investing.com India
Avidity Biosciences director sells shares worth over $228k - Investing.com
Avidity Biosciences director sells shares worth over $228k By Investing.com - Investing.com UK
Mutual of America Capital Management LLC Acquires 40,913 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Breaking Biotech Barriers: Avidity President & CEO Sarah Boyce on RNA’s Next Frontier - Audacy
Avidity Biosciences (NASDAQ:RNA) Trading 4.1% Higher - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Sofinnova Investments Inc. Makes New $875,000 Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Unveiling 7 Analyst Insights On Avidity Biosciences - Benzinga
Avidity Biosciences, Inc. (NASDAQ:RNA) Holdings Boosted by Rhumbline Advisers - MarketBeat
Avidity Biosciences executive sells over $4.5 million in company stock - Investing.com India
Avidity Biosciences executive sells over $4.5 million in company stock By Investing.com - Investing.com Australia
Avidity Biosciences executive sells over $4.5 million in company stock - Investing.com
Avidity Biosciences executive sells over $4.5 million in company stock By Investing.com - Investing.com UK
Certain Restricted stock units of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2024. - Marketscreener.com
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):